The asset behind the next milestones

Avacta (LSE:AVCT), the London and Philadelphia oncology developer, has issued no announcements since 4 November, when it said it would present its dual-payload candidate AVA6207 at a Barcelona symposium on 19 November. Its chief executive and finance chief are also attending a healthcare conference in London from 16 to 19 November. While recent attention has focused on AVA6207 and on survival data for first-generation faridoxorubicin, the company describes AVA6103 as the lead asset of its next-generation platform. This piece reviews what has been disclosed about it, mainly in updates dated 30 September and 23 October 2026.

What AVA6103 is designed to do

AVA6103 links the chemotherapy payload exatecan, a topoisomerase I inhibitor, to a peptide that is cut by fibroblast activation protein, an enzyme abundant around many solid tumours. The aim is to release the drug mainly in the tumour environment, gradually, so that higher doses can be tolerated than with free exatecan. Avacta (LSE:AVCT) positions the approach as an alternative to antibody-drug conjugates such as Enhertu, built with small-molecule chemistry. The company says exatecan resembles the deruxtecan payload in Enhertu.

The clinical data so far

The US Food and Drug Administration cleared the investigational new drug application in January 2026 and the first patient was dosed in March. In September, the company reported preliminary data from the first three dose levels of the FOCUS-01 Phase 1a trial. It said safety was clean so far, including at a payload dose about 50% above the maximum tolerated dose of conventional exatecan, and that pharmacokinetic measurements closely matched preclinical models, with exatecan release visible for days after dosing.

By 23 October, enrolment had been completed at dose level 4, which the company said delivers more than twice the conventional exatecan maximum tolerated dose. The trial selects patients by co-expression of FAP and SLFN11, a gene associated with sensitivity to this class of payload. These are early, small-cohort findings designed to test safety and drug behaviour, not efficacy.

The preclinical claims

At the ESMO congress in October, Avacta (LSE:AVCT) presented mouse studies in which AVA6103 outperformed Enhertu in HER2-positive, FAP-positive gastric tumour models, including tumours that had progressed after Enhertu treatment. The company said treated tumours recruited more FAP-positive fibroblasts over time, which it believes may increase drug delivery. Animal results frequently Fail to translate into human benefit, so these findings support the hypothesis rather than prove it.

Why it matters and the factors to watch

Management has linked partnering discussions for its next-generation Assets to these data. The company expects tumour pharmacokinetic results in late 2026 or early 2027 and first efficacy data in the first half of 2027. Efficacy will be the key test: a clean safety profile matters little unless tumour responses follow.

Funding is a constraint. The October placing and subscription raised £12.5m at 68p, including about £660,000 that four non-executive directors indicated they would subscribe, which the company said would extend its cash runway into the second quarter of 2027; about £2.5m was earmarked for a quarterly Convertible Bond repayment due on 20 October. Cash was £10.59m at 31 August. That runway ends close to the expected efficacy readout, implying further funding or a Partnership may be needed.

Dates to watch

The AVA6207 poster is on 19 November, with candidate selection data expected in the fourth quarter. Further FOCUS-01 updates should follow as dose escalation continues, with tumour pharmacokinetic data due in late 2026 or early 2027. For faridoxorubicin, which the company describes as pending partnering, Phase 1b expansion cohorts continue, and the company said it had agreed certain pivotal trial elements with the FDA. Any partnering deal would change the funding picture materially. Investors may also look for an updated cash figure, since the last one disclosed predates the October raise.